Compare PEBO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | DMAC |
|---|---|---|
| Founded | 1902 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 457.2M |
| IPO Year | N/A | N/A |
| Metric | PEBO | DMAC |
|---|---|---|
| Price | $31.62 | $8.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $34.58 | $15.50 |
| AVG Volume (30 Days) | 156.5K | ★ 581.8K |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $555,347,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | $10.99 | ★ N/A |
| Revenue Growth | ★ 10.92 | N/A |
| 52 Week Low | $26.21 | $3.19 |
| 52 Week High | $35.12 | $10.42 |
| Indicator | PEBO | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 57.59 |
| Support Level | $30.14 | $8.40 |
| Resistance Level | $31.53 | $10.14 |
| Average True Range (ATR) | 0.47 | 0.70 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 90.42 | 35.91 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.